Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
Context: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction. Data Acquisition: We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal/biliary events. Data Synthesis: Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration. Conclusion: Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Indirect evidence to demonstrate that slow pot-prandial gastric emptying should not result in substantial gastric retention 12 hours after the last meal. (A) Six-hour gastric emptying tests (13C- octanoate breath for labeling solid meal components) analyzed using Wagner-Nelson equations were performed in 47 T2D subjects at baseline (black curves, with dotted lines indicating ± 95% confidence intervals). Results from subjects with substantially decelerated gastric emptying (at baseline or 10 weeks after initiating treatment with lixisenatide [20 µg/d] or liraglutide [1.8 mg/d]) are also shown. Gastric emptying curves between 6.5 and 12 hours after meal intake were interpolated assuming an exponential decay (from an initial plateau of 100%) based on the measurements during the initial 6 hours. Even those with slow gastric emptying achieved a gastric content near 0% by 12 hours, which would be a typical interval between a last meal (eg, dinner at 7 Pm) and an early procedure (endoscopy or general anesthesia) in the morning of the following day. Data used for display and modeling are from Quast et al (40). (B) Residual gastric content from food ingested on the previous day (or earlier) as visualized in the gastric antrum by upper gastrointestinal tract endoscopy (courtesy Diabetes Center Bad Lauterberg). Abbreviations: T2D, type 2 diabetes.](https://figures.cochat.ai/paper-figures/7d35bedb7ee940febd956b76a9173f53/clinical-consequences-of-delayed-gastric-emptying-with-glp-1-receptor-agonists-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activation of its GLP-1 component also delays gastric emptying, blunting postprandial glucose excursions and contributing to steadier overall glucose profiles [69].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The second is pharmacokinetic: GLP-1 agonists slow gastric emptying and so alter the absorption rate of oral drugs [47,120], while berberine inhibits enzymes and transporters at the same intestinal interface, so the two perturb one process from different directions [46,47].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [120]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This difference is believed to result from tachyphylaxis associated with prolonged GLP-1 RA use, leading to attenuation of the gastric emptying–delaying effect, which becomes more evident with long-acting formulations [32,33].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Based on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and…”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 1×
“Monnier at al reported that PPG is a dominant contributor to overall glycemia in T2D (as assessed by measurement of hemoglobin A 1c ), especially in well-controlled diabetes [calculated to contribute approximately 70% when hemoglobin A 1c is ≤ 7.3% (3)].”
InfluentialGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“…on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and obesity.”
Identifying and Avoiding Bias in Research
Pannucci, C. J., & Wilkins, E. G. (2010) · Plastic and Reconstructive Surgery · doi:10.1097/prs.0b013e3181de24bc · Cited by 1,079 · cited 1×
“…to see what one expects to see (eg, in studies where the examiner was not blinded to the patients ’ health status or treatment); publication bias describes the fact that results not compatible with the original hypothesis have a lesser chance to be submitted or accepted for publication (116).”
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“…refer to Supplementary Table S1 for more data on the effect of GLP-1 receptor agonists on gastric emptying in subjects with type 2 diabetes and obesity. imprecise measurement techniques (31) like the paracetamol (acetaminophen) absorption technique, which continues to be used extensively (32-34).”
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 1×
“While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through both parasympathetic (vagal) afferents and direct central nervous stimulation (85-87).”
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“Accordingly, a possible mechanism of action of GLP-1 RAs to reduce appetite and energy intake may involve interaction with neurons in the hypothalamus either directly (66, 67) or via the nodose ganglion (68), rather than a secondary consequence of slowing gastric emptying.”
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 1×
“This dose-dependent slowing of gastric emptying represents a major mechanism contributing to PPG lowering by exogenous GLP-1 and, in healthy humans, “ outweighs ” its insulinotropic effects such that postprandial insulin secretory responses are suppressed rather than stimulated (15, 16).”
Self-citationVantrappen, G., Janssens, J., Hellemans, J., & Ghoos, Y. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108740 · Cited by 815 · cited 1×
“…phase 3 of this complex, which is composed of pressure waves often originating in the stomach and propagated segment by segment toward the duodenum and jejunum (108), which is thought to clear the remnants of the preceding meal including indigestible gastric content from the stomach (108, 109).”
Clinical Significance of Pulmonary Aspiration during the Perioperative Period
Warner, M. A., Warner, M. E., & Weber, J. G. (1993) · Anesthesiology · doi:10.1097/00000542-199301000-00010 · Cited by 808 · cited 1×
“This is a rare complication of general anesthesia, with an incidence of approximately 1 per 3000 elective surgery cases, resulting in death in approximately 1 per 70 000 cases (106).”
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“Accordingly, a possible mechanism of action of GLP-1 RAs to reduce appetite and energy intake may involve interaction with neurons in the hypothalamus either directly (66, 67) or via the nodose ganglion (68), rather than a secondary consequence of slowing gastric emptying.”
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“Acute IV administration of GLP-1 slows gastric emptying profoundly and dose-dependently (12), accompanied by relaxation of the gastric fundus, increased gastric compliance, inhibition of antral contractility, and increased pyloric tone (13, 14).”
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023) · JAMA · doi:10.1001/jama.2023.19574 · Cited by 471
Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469 · cited 1×
“Gastric emptying is now recognized as a major determinant of postprandial glycemic excursions in both healthy subjects (6) and people with diabetes (7) and accounts for about a third of the variance in the initial rise in glucose postoral challenge (ie, first 15-30 minutes) (6).”
Self-citationGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427
Gastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus
Horowitz, M., Harding, P. E., Maddox, A. F., Wishart, J. M., Akkermans, L. M. A., Chatterton, B. E., & Shearman, D. J. C. (1989) · Diabetologia · doi:10.1007/bf00265086 · Cited by 392 · cited 1×
“The majority of studies that have evaluated the relationship between the effects of GLP-1RAs on gastric emptying and gastrointestinal symptoms in health, obesity, or T2D have found no or weak correlations (45-49).”
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 2×
“Nauck et al evaluated the effect of exogenous IV GLP-1 (7-36 amide), delivered at 0.8 pmol.kg − 1. l − 1 for 8 hours, on gastric emptying (by a dye dilution technique) of 2 successive meals consumed at baseline and after 4 hours of GLP-1 exposure (19).”
InfluentialSelf-citationRaz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351 · cited 1×
“A few robust clinical trials have explored the impact of reducing PPG on vascular complications, with evidence of beneficial impacts on both microvascular (eg, retinopathy) and macrovascular (eg, cardiovascular) disease (4, 5).”
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Braden, B., Adams, S., Duan, L.-P., Orth, K.-H., Maul, F.-D., Lembcke, B., Hör, G., & Caspary, W. F. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90202-3 · Cited by 294 · cited 1×
“The stable isotope breath test represents an acceptable alternative that is noninvasive, simple to perform, and readily available and has been validated against scintigraphy (38, 39, 41).”
Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2010) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 275
Gastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273 · cited 2×
“Scintigraphy remains the gold-standard technique but is limited by cost, availability, and exposure to ionizing radiation (37).”
Self-citationKnockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269 · cited 1×
“While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through both parasympathetic (vagal) afferents and direct central nervous stimulation (85-87).”
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · cited 2×
“The overall magnitude of both slowing of gastric emptying and glucose-lowering were marked but variable and dependent on the baseline rate of gastric emptying and less prominent in those with slow baseline gastric emptying (23).”
Self-citationSilveira, S. Q., da Silva, L. M., de Campos Vieira Abib, A., de Moura, D. T. H., de Moura, E. G. H., Santos, L. B., Ho, A. M.-H., Nersessian, R. S. F., Lima, F. L. M., Silva, M. V., et al. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111091 · Cited by 259 · cited 3×
“Same-day colonoscopy has been observed to have a protective effect (prevalence ratio 0.25, 95% CI 0.16-0.39, P .001), possibly because of prolonged abstinence for solid food, particularly in - digestible solids, and the liquid diet that is prescribed for the day prior to the procedure (51, 101).”
InfluentialLiu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Baggio, L. L., & Drucker, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78371 · Cited by 245 · cited 1×
“Accordingly, a possible mechanism of action of GLP-1 RAs to reduce appetite and energy intake may involve interaction with neurons in the hypothalamus either directly (66, 67) or via the nodose ganglion (68), rather than a secondary consequence of slowing gastric emptying.”
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245 · cited 1×
“…refer to Supplementary Table S1 for more data on the effect of GLP-1 receptor agonists on gastric emptying in subjects with type 2 diabetes and obesity. imprecise measurement techniques (31) like the paracetamol (acetaminophen) absorption technique, which continues to be used extensively (32-34).”
Gastric distension and gastric capacity in relation to food intake in humans
Geliebter, A. (1988) · Physiology & Behavior · doi:10.1016/0031-9384(88)90333-2 · Cited by 243 · cited 1×
“Since gastric distension (both of the proximal and distal stomach) can lead to reduced food/energy intake (64, 65), the question arises as to whether the slowing of gastric emptying, via increased gastric distension, contributes to the regulation of appetite and energy intake.”
Deane, A. M., Nguyen, N. Q., Stevens, J. E., Fraser, R. J. L., Holloway, R. H., Besanko, L. K., Burgstad, C., Jones, K. L., Chapman, M. J., Rayner, C. K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1503 · Cited by 238 · cited 2×
“…injections for 1 week is expected to reduce plasma concentrations to approximately half this value, still > 20-fold higher than physiological concentrations, which is sufficient to decelerate gastric emptying, as indicated by studies employing the GLP-1 receptor antagonist exendin (9-39) (17).”
Self-citationHalawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224 · cited 1×
“Mean gastric half-emptying times are prolonged after 5 weeks of treatment but significantly less so after 16 weeks (29).”
Little, T. J., Pilichiewicz, A. N., Russo, A., Phillips, L., Jones, K. L., Nauck, M. A., Wishart, J., Horowitz, M., & Feinle-Bisset, C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2220 · Cited by 212 · cited 2×
“However, this may not be sufficient to reduce the risk of retained gastric contents and/or aspiration events, as the dose-response relationship suggests that even physiological concentrations of intact GLP-1 are sufficient to slow gastric emptying (16, 17).”
Self-citationChoi, M., Camilleri, M., Burton, D., Zinsmeister, A., Forstrom, L., & Nair, K. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70126-4 · Cited by 205 · cited 3×
“Conversely, in rats, antagonism of GLP-1 signaling by exendin [ 9-39 9-39 ] augments lymph”
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia
Sen, S., Potnuru, P. P., Hernandez, N., Goehl, C., Praestholm, C., Sridhar, S., & Nwokolo, O. O. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2024.0111 · Cited by 202
Relation between postprandial satiation and antral area in normal subjects
Jones, K., Doran, S., Hveem, K., Bartholomeusz, F., Morley, J., Sun, W., Chatterton, B., & Horowitz, M. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/66.1.127 · Cited by 194 · cited 2×
“In the absence of GLP-1 RA treatment, the presence of symptoms is not a direct indicator of delayed gastric emptying (27, 50).”
Self-citationUmapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193 · cited 2×
“…et al compared the effects of acute, intermittent (2 4.5-hour infusions separated by 20 hours) and continuous (20 hours) IV GLP-1 (0.8 pmol.kg − 1. min − 1 ) with placebo on gastric emptying (with scintigraphy, the gold-standard measurement) in a double-blind crossover study in healthy humans (20).”
InfluentialSelf-citationGuideline for management of postmeal glucose in diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.08.002 · Cited by 183 · cited 1×
“Elevation of postprandial glycemia (PPG) is characteristically the initial defect in glucose intolerance (1) and is a challenging aspect of the management of T2D (2).”
Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management
Du, Y. T., Rayner, C. K., Jones, K. L., Talley, N. J., & Horowitz, M. (2018) · Diabetes Care · doi:10.2337/dc17-1536 · Cited by 180 · cited 2×
“…frequently with GLP-1RAs (42) and have a major influence on the adherence to such treatment over time, have often been assessed in clinical trials solely via participant self-report, which is known to be unrelaible (eg, symptoms may not be volunteered due to embarrassment or poor recall) (43, 44).”
Self-citationHorowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · cited 2×
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
InfluentialSelf-citationGastric emptying in early noninsulin-dependent diabetes mellitus.
Jones, K. L., Horowitz, M., Carney, B. I., Wishart, J. M., Guha, S., & Green, L. (1996) · PubMed · Cited by 175
Self-citationLarsen, J., Hylleberg, B., Ng, K., & Damsbo, P. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1416 · Cited by 171 · cited 1×
“…receptor antagonist, exendin The observation that IV GLP-1 leads to a reduction in plasma glucose after a meal in individuals with T2D, while a rise in plasma glucose was observed after subsequent meals (18), suggested there may be tachyphylaxis for the effects of GLP-1 to slow gastric emptying.”
Xiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.246207 · Cited by 164 · cited 1×
“Of note, exenatide is effective in suppressing the production of chylomicrons and the rise of apoB-48 in the circulation, following administration of a lipid-containing “ meal ” directly into the small intestine in individuals without diabetes (74).”
Hellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160 · cited 1×
“…infusions of native GLP-1 that achieve either physiological or supraphysiological plasma concentrations are associated with inhibition of the migrating motor complex (83) and a decrease in the number and amplitude of duodenal pressure waves during both fasting and intraduodenal lipid infusion (14).”
Continued Reduction in the Prevalence of Retinopathy in Adolescents With Type 1 Diabetes
Downie, E., Craig, M. E., Hing, S., Cusumano, J., Chan, A. K. F., & Donaghue, K. C. (2011) · Diabetes Care · doi:10.2337/dc11-0102 · Cited by 153 · cited 1×
“A few robust clinical trials have explored the impact of reducing PPG on vascular complications, with evidence of beneficial impacts on both microvascular (eg, retinopathy) and macrovascular (eg, cardiovascular) disease (4, 5).”
Lorenz, M., Pfeiffer, C., Steinsträßer, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 149 · cited 1×
“Lorenz et al reported slowing of gastric emptying, assessed by a stable isotope ( 13 C octanoic acid) breath test, following 4 weeks of treatment with lixisenatide, accompanied by a reduction in postprandial glucose excursions (25).”
Self-citationGibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14255 · Cited by 149 · cited 1×
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
Gastric distention by balloon and test-meal intake in obese and lean subjects
Geliebter, A., Westreich, S., & Gage, D. (1988) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/48.3.592 · Cited by 148 · cited 1×
“Since gastric distension (both of the proximal and distal stomach) can lead to reduced food/energy intake (64, 65), the question arises as to whether the slowing of gastric emptying, via increased gastric distension, contributes to the regulation of appetite and energy intake.”
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146 · cited 2×
“Intravenous erythromycin ( ∼ 3 mg/kg) has been shown to reverse the delay in gastric emptying induced by exogenous GLP-1 (123), and the same dose has been shown to initiate interdigestive motility in healthy human subjects (124).”
Self-citationSchirra, J., Houck, P., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2000) · Gut · doi:10.1136/gut.46.5.622 · Cited by 145 · cited 4×
“…infusions of native GLP-1 that achieve either physiological or supraphysiological plasma concentrations are associated with inhibition of the migrating motor complex (83) and a decrease in the number and amplitude of duodenal pressure waves during both fasting and intraduodenal lipid infusion (14).”
InfluentialAdverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145 · cited 1×
“…adverse effects have not been evident in large randomized controlled studies involving these agents, there are several case reports linking these potentially serious conditions to the use of GLP-1RAs (88, 89) and the dual incretin receptor agonist tir-zepatide (90) in people with and without T2D.”
Kobori, T., Onishi, Y., Yoshida, Y., Tahara, T., Kikuchi, T., Kubota, T., Iwamoto, M., Sawada, T., Kobayashi, R., Fujiwara, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14005 · Cited by 144
Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14110 · Cited by 143 · cited 1×
“While inexpensive and simple to perform, its limitations are partitioning in the liquid phase and the inability to assess gastric emptying of solids reliably (31, 35, 36).”
Self-citationUshakumari, D. S., & Sladen, R. N. (2024) · Anesthesiology · doi:10.1097/aln.0000000000004776 · Cited by 139 · cited 1×
“The American Society of Anesthesiologists has suggested withholding short-acting GLP-1RAs for 1 day and long-acting GLP-1RAs for 1 week prior to the procedure (117).”
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138 · cited 1×
“This is surprising, since the overall incidence of gastrointestinal adverse events is much higher with the latter class (98).”
Self-citationSchirra, J., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2002) · Gut · doi:10.1136/gut.50.3.341 · Cited by 130 · cited 1×
“Acute IV administration of GLP-1 slows gastric emptying profoundly and dose-dependently (12), accompanied by relaxation of the gastric fundus, increased gastric compliance, inhibition of antral contractility, and increased pyloric tone (13, 14).”
Marbury, T. C., Flint, A., Jacobsen, J. B., Derving Karsbøl, J., & Lasseter, K. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0528-2 · Cited by 130 · cited 1×
“With an elimination half-life of 7.6 days (119), pausing semaglutide injections for 1 week is expected to reduce plasma concentrations to approximately half this value, still > 20-fold higher than physiological concentrations, which is sufficient to decelerate gastric emptying, as indicated by…”
InfluentialYeo, Y. H., Gaddam, S., Ng, W. H., Huang, P.-C., Mohamed, G., Samaan, J., Yi-Jin Hsieh, T., Lee, G. Y., Watson, R., Mathur, R., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.03.015 · Cited by 128 · cited 2×
“In the largest study by Yeo et al (112) of 963 184 individuals who underwent endoscopy, 46 935 (4.9”
InfluentialNakatani, Y., Maeda, M., Matsumura, M., Shimizu, R., Banba, N., Aso, Y., Yasu, T., & Harasawa, H. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.009 · Cited by 126 · cited 1×
“Similar phenomena are evident with the use of exenatide (24), which has been shown to inhibit small intestinal motility and increase gastrointestinal transit time in individuals with and without T2D (84).”
Gonlachanvit, S., Hsu, C.-W., Boden, G. H., KNIGHT, L. C., Maurer, A. H., Fisher, R. S., & Parkman, H. P. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1022528414264 · Cited by 119 · cited 1×
“Modulating gastric emptying, such as accelerating emptying using a prokinetic agent such as erythromycin or retarding it with morphine (10) or nutrient preloads (eg, protein) (11), has been shown to acutely increase or decrease PPG excursions, respectively, in T2D.”
Marathe, C. S., Horowitz, M., Trahair, L. G., Wishart, J. M., Bound, M., Lange, K., Rayner, C. K., & Jones, K. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2482 · Cited by 97 · cited 1×
“However, in people with impaired glucose tolerance or T2D, a “ right-ward shift ” is observed, such that a direct positive relationship is observed even beyond 60 minutes (8).”
Self-citationPreoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C., & Sun, E. C. (2024) · JAMA · doi:10.1001/jama.2024.5003 · Cited by 94 · cited 1×
“Regarding the aspiration risk with emergency surgery, Dixit et al (115) studied 23 679 patients of whom 3502 (14.8”
InfluentialVardarli, I., Arndt, E., Deacon, C. F., Holst, J. J., & Nauck, M. A. (2014) · Diabetes · doi:10.2337/db13-0805 · Cited by 92 · cited 1×
“…week injected subcutaneously have been reported to be approximately 40 nmol/L. Assuming that 99% is albumin-bound, only 1% (400 pmol/L) is free to diffuse into tissues and bind to GLP-1 receptors, but these concentrations are > 40-fold higher than physiological intact GLP-1 concentrations (118).”
Self-citationNakajima, K., Nagamine, T., Fujita, M., Ai, M., Tanaka, A., & Schaefer, E. J. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800263-6.00003-3 · Cited by 89 · cited 1×
“Chylomicrons are large triglyceride-rich lipoproteins that contain a unique surface apolipoprotein B-48 (ApoB-48) (69) and are assembled in enterocytes from dietary lipids.”
Schlögl, H., Kabisch, S., Horstmann, A., Lohmann, G., Müller, K., Lepsien, J., Busse-Voigt, F., Kratzsch, J., Pleger, B., Villringer, A., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1925 · Cited by 88 · cited 1×
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
Dahl, K., Brooks, A., Almazedi, F., Hoff, S. T., Boschini, C., & Bækdal, T. A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14373 · Cited by 87
Jalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87
Self-citationThazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J., Kuo, P., Checklin, H. L., Bound, M. J., Rigda, R. S., Crouch, B., et al. (2016) · Diabetes · doi:10.2337/db15-0893 · Cited by 83 · cited 2×
“Similar phenomena are evident with the use of exenatide (24), which has been shown to inhibit small intestinal motility and increase gastrointestinal transit time in individuals with and without T2D (84).”
Self-citationIncretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2430 · Cited by 67 · cited 3×
“A study using 2 data repositories from the United Kingdom included data from 25 617 subjects treated with GLP-1RAs and compared the rate of bowel obstruction with 67 261 subjects treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors using propensity-score matching (91).”
InfluentialJones, K. L., Rigda, R. S., Buttfield, M. D. M., Hatzinikolas, S., Pham, H. T., Marathe, C. S., Wu, T., Lange, K., Trahair, L. G., Rayner, C. K., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13633 · Cited by 66 · cited 2×
“Thus, lixisenatide, as a representative of short-acting GLP-1 RAs, profoundly decelerated gastric emptying of a liquid meal, with little difference over time (single dose vs 8 weeks), supporting the absence of substantial tachyphylaxis (26, 27).”
Self-citationQuast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dc20-0720 · Cited by 64 · cited 1×
“Data used for display and modeling are from Quast et al (40).”
Self-citationRehfeld, J. F., Knop, F. K., Asmar, A., Madsbad, S., Holst, J. J., & Asmar, M. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2018.1530297 · Cited by 62 · cited 1×
“Moreover, both GLP-1 (70) and GLP-1RAs [eg, exenatide (71), albiglutide (72), and liraglutide (73)] have been shown to inhibit gallbladder emptying and refilling and to potentially reduce the discharge of bile into the small intestine, in-terrupting the subsequent emulsification and digestion of…”
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
Keller, J., Trautmann, M. E., Haber, H., Tham, L. S., Hunt, T., Mace, K., & Linnebjerg, H. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.005 · Cited by 61 · cited 1×
“Moreover, both GLP-1 (70) and GLP-1RAs [eg, exenatide (71), albiglutide (72), and liraglutide (73)] have been shown to inhibit gallbladder emptying and refilling and to potentially reduce the discharge of bile into the small intestine, in-terrupting the subsequent emulsification and digestion of…”
Baettig, S. J., Filipovic, M. G., Hebeisen, M., Meierhans, R., & Ganter, M. T. (2023) · Anaesthesia · doi:10.1111/anae.16117 · Cited by 59 · cited 1×
“There may be a role for point-of-care gastric ultrasound as a noninvasive, cost-effective strategy to identify patients on GLP-1RA-based therapy with retained gastric contents (121, 122).”
Watson, L. E., Phillips, L. K., Wu, T., Bound, M. J., Checklin, H. L., Grivell, J., Jones, K. L., Clifton, P. M., Horowitz, M., & Rayner, C. K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13604 · Cited by 58 · cited 3×
“Gastric emptying may be markedly delayed in the absence of symptoms, and in some individuals with severe symptoms, gastric emptying may be normal or accelerated (11).”
Self-citationRisks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
Klonoff, D. C., Kim, S. H., Galindo, R. J., Joseph, J. I., Garrett, V., Gombar, S., Aaron, R. E., Tian, T., & Kerr, D. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15636 · Cited by 58 · cited 1×
“Klonoff et al (114) evaluated the risk of postoperative complications in 13 661 people with diabetes, of whom 2256 (16.5”
InfluentialGarza, K., Aminpour, E., Shah, J., Mehta, B., Early, D., Gyawali, C. P., & Kushnir, V. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002777 · Cited by 57 · cited 1×
“The presence of microvascular or macrovascular complications of T2D was associated with a greater incidence of retained gastric contents (15% vs 2%, P < .01), as was use of insulin (17% vs 5%, P < .01) (104).”
Barlowe, T. S., Anderson, C., Sandler, R. S., Subramaniam, D., Muratore, A., Buse, J. B., Gouker, L. N., Majithia, R. T., Shaheen, N. J., Stürmer, T., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.04.038 · Cited by 55
McMAHON, M., MARSH, H., & RIZZA, R. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-3-647 · Cited by 53 · cited 1×
“This 6-hour period coincides with the time during which labeled glucose enters the circulation after oral glucose or mixed meals (107).”
Wu, T., Ma, J., Bound, M. J., Checklin, H., Deacon, C. F., Jones, K. L., Horowitz, M., & Rayner, C. K. (2014) · Diabetes · doi:10.2337/db13-1627 · Cited by 52 · cited 1×
“This raises the question as to whether, if there is an effect, the underlying mechanisms do not relate to inhibitory effects on motility, since DPP-4 inhibitors appear to have little to no effect on this parameter in either obese subjects or those with T2D (99).”
Self-citationNexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51
Nadeem, D., Taye, M., Still, M. D., McShea, S., Satterfield, D., Dove, J. T., Wood, G. C., Addissie, B. D., Diehl, D. L., Johal, A. S., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.04.2900 · Cited by 48
Paracetamol as a Post Prandial Marker for Gastric Emptying, A Food-Drug Interaction on Absorption
Bartholomé, R., Salden, B., Vrolijk, M. F., Troost, F. J., Masclee, A., Bast, A., & Haenen, G. R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136618 · Cited by 43 · cited 1×
“While inexpensive and simple to perform, its limitations are partitioning in the liquid phase and the inability to assess gastric emptying of solids reliably (31, 35, 36).”
Basolo, A., Burkholder, J., Osgood, K., Graham, A., Bundrick, S., Frankl, J., Piaggi, P., Thearle, M. S., & Krakoff, J. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.017 · Cited by 43
Flint, A., Kapitza, C., & Zdravkovic, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12108 · Cited by 42 · cited 1×
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Pietiläinen, K. H., Ainola, M., Hakkarainen, A., Lundbom, N., Fuchs, J., Thorsell, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14328 · Cited by 40
Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 40 · cited 1×
“Similarly, the evaluation of gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which occur frequently with GLP-1RAs (42) and have a major influence on the adherence to such treatment over time, have often been assessed in clinical trials solely via participant self-report, which is…”
Basal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 39 · cited 1×
“Elevation of postprandial glycemia (PPG) is characteristically the initial defect in glucose intolerance (1) and is a challenging aspect of the management of T2D (2).”
Quast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14477 · Cited by 39 · cited 3×
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
Self-citationShoemaker, A. H., Silver, H. J., Buchowski, M., Slaughter, J. C., Yanovski, J. A., Elfers, C., Roth, C. L., & Abuzzahab, M. J. (2022) · International Journal of Obesity · doi:10.1038/s41366-021-01043-6 · Cited by 38 · cited 1×
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01202-1 · Cited by 38
Self-citationClinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists
Firkins, S. A., Yates, J., Shukla, N., Garg, R., Vargo, J. J., Lembo, A. J., Simons-Linares, R., & Butsch, W. S. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.013 · Cited by 38 · cited 1×
“Same-day colonoscopy has been observed to have a protective effect (prevalence ratio 0.25, 95% CI 0.16-0.39, P .001), possibly because of prolonged abstinence for solid food, particularly in - digestible solids, and the liquid diet that is prescribed for the day prior to the procedure (51, 101).”
InfluentialIncretin-based drugs and intestinal obstruction: A pharmacovigilance study
Gudin, B., Ladhari, C., Robin, P., Laroche, M.-L., Babai, S., Hillaire-Buys, D., & Faillie, J.-L. (2020) · Therapies · doi:10.1016/j.therap.2020.02.024 · Cited by 37 · cited 2×
“It should be appreciated that, in general, the use of DPP-4 inhibitors in these studies was associated with a higher risk of intestinal obstruction than GLP-1RAs (91, 92, 96, 97).”
Ueda, P., Wintzell, V., Melbye, M., Eliasson, B., Söderling, J., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Svanström, H., Hviid, A., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.08.034 · Cited by 34 · cited 2×
“It should be appreciated that, in general, the use of DPP-4 inhibitors in these studies was associated with a higher risk of intestinal obstruction than GLP-1RAs (91, 92, 96, 97).”
Camilleri, M., Carlson, P., & Dilmaghani, S. (2023) · Obesity · doi:10.1002/oby.23941 · Cited by 34 · cited 1×
“However, a secondary analysis of the same data shows substantial interindividual variability in the effects of liraglutide on gastric emptying and regarding the temporal pattern of effects of this long-acting GLP-1 RA (30).”
Bae, J. H., Choi, H. J., Cho, K. I. K., Kim, L. K., Kwon, J. S., & Cho, Y. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0018 · Cited by 33
Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01176 · Cited by 32
Glucagon‐like peptide‐1 receptor agonists and the appropriate measurement of gastric emptying
Horowitz, M., Rayner, C. K., Marathe, C. S., Wu, T., & Jones, K. L. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14166 · Cited by 32 · cited 2×
“While inexpensive and simple to perform, its limitations are partitioning in the liquid phase and the inability to assess gastric emptying of solids reliably (31, 35, 36).”
Self-citationChapman, M. B., Norwood, D. A., Price, C., Abdulhadi, B., Kyanam Kabir Baig, K., Ahmed, A. M., Peter, S., Routman, J. S., Sánchez-Luna, S. A., Duggan, E. W., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.05.012 · Cited by 32 · cited 1×
“6) from liquids (103), there was still a higher incidence of retained gastric contents in GLP-1RA users.”
Tremblay, A. J., Lamarche, B., Kelly, I., Charest, A., Lépine, M. ‐., Droit, A., & Couture, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12359 · Cited by 31
Jalleh, R., Pham, H., Marathe, C. S., Wu, T., Buttfield, M. D., Hatzinikolas, S., Malbert, C. H., Rigda, R. S., Lange, K., Trahair, L. G., et al. (2020) · Nutrients · doi:10.3390/nu12071962 · Cited by 29 · cited 8×
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
InfluentialSelf-citationAssociation Between Symptoms, Quality of Life, and Gastric Emptying in Dyspeptic Patients
Wuestenberghs, F., Juge, M., Melchior, C., Desprez, C., Leroi, A.-M., & Gourcerol, G. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19060 · Cited by 28
Maselli, D. B., Lee, D., Bi, D., Jirapinyo, P., Thompson, C. C., Donnangelo, L. L., & McGowan, C. E. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07278-2 · Cited by 28 · cited 1×
“Maselli et al (110), in a retrospective study of 57 adults on GLP-1RA-based therapy, reported that having a 24-hour liquid-only diet and a 12-hour fast resulted in no instances of retained gastric solids, pulmonary aspiration, gastro-oesophageal regurgitation, or hypoxia.”
Clinical significance of scintigraphic rapid gastric emptying
Balan, K., Sonoda, L. I., Seshadri, N., Solanki, C., & Middleton, S. (2011) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32834bf262 · Cited by 26
Dubé, M., D'Amours, M., & Weisnagel, S. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14050 · Cited by 25 · cited 3×
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
Comparison between physiologic and erythromycin-induced interdigestive motility.
Björnsson, E., & Abrahamsson, H. (1995) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529509093252 · Cited by 24 · cited 1×
“Intravenous erythromycin ( ∼ 3 mg/kg) has been shown to reverse the delay in gastric emptying induced by exogenous GLP-1 (123), and the same dose has been shown to initiate interdigestive motility in healthy human subjects (124).”
Shaddinger, B. C., Young, M. A., Billiard, J., Collins, D. A., Hussaini, A., & Nino, A. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.940 · Cited by 22 · cited 1×
“Moreover, both GLP-1 (70) and GLP-1RAs [eg, exenatide (71), albiglutide (72), and liraglutide (73)] have been shown to inhibit gallbladder emptying and refilling and to potentially reduce the discharge of bile into the small intestine, in-terrupting the subsequent emulsification and digestion of…”
Nahmias, A., Stahel, P., Tian, L., Xiao, C., & Lewis, G. F. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.316311 · Cited by 22
Retained Food During Esophagogastroduodenoscopy Is a Risk Factor for Gastric-to-Pulmonary Aspiration
Feighery, A. M., Oblizajek, N. R., Vogt, M. N. P., Bi, D., League, J. B., Buttar, N. S., & Prichard, D. O. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07536-2 · Cited by 22 · cited 1×
“Residual food may increase the risk of perioperative pulmonary aspiration (105).”
Baldawi, M., Ghaleb, N. A., McKelvey, G. M., Ismaeil, Y. M., & Saasouh, W. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111365 · Cited by 22 · cited 1×
“Baldawi et al published a meta-analysis of studies assessing residual gastric content by ultrasonography (111).”
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia
Novodvorský, P., & Haluzík, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00982-3 · Cited by 21
The 1-Hour Plasma Glucose: Common Link Across the Glycemic Spectrum
Bergman, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.752329 · Cited by 20 · cited 3×
“Conversely, in rats, antagonism of GLP-1 signaling by exendin [ 9-39 9-39 ] augments lymph”
Trahair, L. G., Nauck, M. A., Wu, T., Stevens, J. E., Buttfield, M. D., Hatzinikolas, S., Pham, H., Meier, J. J., Rayner, C. K., Horowitz, M., et al. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1784-6185 · Cited by 20 · cited 1×
“The stable isotope breath test represents an acceptable alternative that is noninvasive, simple to perform, and readily available and has been validated against scintigraphy (38, 39, 41).”
Self-citationJalleh, R. J., Jones, K. L., Nauck, M., & Horowitz, M. (2023) · Annals of Internal Medicine · doi:10.7326/m23-2019 · Cited by 18 · cited 2×
“…frequently with GLP-1RAs (42) and have a major influence on the adherence to such treatment over time, have often been assessed in clinical trials solely via participant self-report, which is known to be unrelaible (eg, symptoms may not be volunteered due to embarrassment or poor recall) (43, 44).”
Self-citationIs Making the Stomach Pump Better the Answer to Gastroparesis?
Rayner, C. K., Jones, K. L., & Horowitz, M. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.030 · Cited by 16 · cited 1×
“The majority of studies that have evaluated the relationship between the effects of GLP-1RAs on gastric emptying and gastrointestinal symptoms in health, obesity, or T2D have found no or weak correlations (45-49).”
Self-citationA RARE CASE OF A LARGE BOWEL OBSTRUCTION DUE TO TIRZEPATIDE
GORDON, A., DIXIT, K., Shachi, T., Salonia, J. S., & Seltzer, E. S. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.07.1569 · Cited by 11 · cited 1×
“…adverse effects have not been evident in large randomized controlled studies involving these agents, there are several case reports linking these potentially serious conditions to the use of GLP-1RAs (88, 89) and the dual incretin receptor agonist tir-zepatide (90) in people with and without T2D.”
Bennett, D., Davé, S., Sakaguchi, M., Chang, C., & Dolin, P. (2016) · Diabetology International · doi:10.1007/s13340-016-0261-3 · Cited by 8 · cited 1×
“It should be appreciated that, in general, the use of DPP-4 inhibitors in these studies was associated with a higher risk of intestinal obstruction than GLP-1RAs (91, 92, 96, 97).”
Gandhi, A., Khanam, V., Peterson, D., Patel, F., & Kulairi, Z. I. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa046.609 · Cited by 7 · cited 1×
“…adverse effects have not been evident in large randomized controlled studies involving these agents, there are several case reports linking these potentially serious conditions to the use of GLP-1RAs (88, 89) and the dual incretin receptor agonist tir-zepatide (90) in people with and without T2D.”
Mather, K. J., Coşkun, T., Pratt, E. J., Miličević, Z., Weerakkody, G. J., Thomas, M. K., Haupt, A., & Ruotolo, G. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15365 · Cited by 7
Research works printed but not linked: 3
- Schick RR, Zimmermann JP, vorm Walde T, Schusdziarra V, Classen M. Glucagon-like peptide (GLP)-1(7-36)-amide: a central suppressor of food intake in rats (abstract). Gastroenterol. 1992; 102: A756.
- Code CF, Schlegel JF. The gastrointestinal interdigestive housekeeper: motor correlates of the interdigestive myoelectric complex of the dog. In: Daniel EE, Gilbert JAL, Schofield B, Schnitka TK, Scott G, eds. Proceedings of the Fourth International Symposium on Gastrointestinal Motility. Vancouver Mitchell Press Ltd.; 1974: 631‐ 634.
- American Gastroenterological Association. AGA does not endorse all patients stopping popular diabetes and weight loss drugs prior to endoscopy. 2023. Accessed May 28, 2024. https://gastro.org/press-releases/continue-glp1-drugs-before-endoscopy/
Cited by
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 135
HOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 70
Self-citationUllah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“The maximum duration of any of the few studies in which a good technique has been used to quantify emptying (usually scintigraphy) is 16 weeks, and while the magnitude of the delay in emptying at that time point was not as marked as at 5 weeks, it was substantial in some cases (47).”
Self-citationCedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 28
Metadata
- Authors
- Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A.
- Affiliations
- Royal Adelaide Hospital (AU)
- St. Josef-Hospital (DE)
- The University of Adelaide (AU)
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Nauck, Michael A
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2024-10-17
- Volume
- 110
- Issue
- 1
- Pages
- 1-15
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC11651700
- OpenAlex
- W4403479516
- Cited by
- 157
- References
- 120
- Citations by year
- 2026: 110 · 2025: 45 · 2024: 2
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Funders
- Mary Overton postdoctoral fellowship
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- GLP-1 receptor agonists, tirzepatide, delayed gastric emptying, pulmonary aspiration, upper gastrointestinal endoscopy, periprocedural management, type 2 diabetes, obesity, tachyphylaxis, prokinetic agents, erythromycin, point-of-care ultrasound, gastrointestinal adverse effects
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Emptying, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Gastroparesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.